Amicus Therapeutics - All Time High

Amicus Therapeutics (FOLD) is the Barchart Chart of the Day,  The biopharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha of 274.60+ and gained 328.00% in the last year.

The Chart of the Day belongs to Amicus Therapeutics (FOLD).  I found the biopharmaceutical stock by using Barchart to sort today's All Time High list for the stocks with the highest Weighted Alpha then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 5/26 the stock gained 55.34%.

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 96% Barchart technical buy signals
• 274.60+ Weighted Alpha
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 13 new highs and up 32.29% in the last month
• Relative Strength Index 74.20%
• Barchart computes a technical support level at 17.58
• Recently traded at 18.19 with a 50 day moving average of 14.48

Fundamental factors:

• Market Cap $2.06 billion
• Revenue expected to grow 3,808.90 next year
• Earnings estimated to increase 24.80% next year
• Wall Street analysts issued 2 strong buy and 3 buy recommendations on the stock

None of the normal technical trading strategies have been reliable for this stock so I'd advise you use a trailing stop loss 10% below the previous high.